Truist analyst Richard Newitter lowered the firm’s price target on Glaukos (GKOS) to $135 from $140 but keeps a Buy rating on the shares. The company’s Q1 is unlikely to ‘re-validate’ the bull-case iDose ramp, but the firm still believes that it’s a matter of “when, not if,” that validation is nearing, the analyst tells investors in a research note. Coverage progress highlighted on the earnings call points to a higher level of visibility into a steepening iDose trajectory, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Wells downgrades Glaukos with iDose growth priced in
- Glaukos downgraded to Equal Weight from Overweight at Wells Fargo
- Positive Buy Rating for Glaukos Amid Strong iDose Performance and Awaited FDA Decision
- Glaukos’s Promising Outlook: Buy Rating Amid Strong Sales and Strategic Growth Opportunities
- Glaukos Corp. Reports Strong Q1 2025 Growth